01 May 2006
Bifenthrin causes neurite retraction in the absence of cell death: A modelfor pesticide associated neurodegeneration.
Avishek Nandi, Daljit Chandi, Rethabile Lechesa, Stephen C. Pryor, Ashlea McLaughlin, Josephine A. Bonventre, Katherine Flynn, Benjamin S. WeeksMed Sci Monit 2006; 12(5): BR169-173 :: ID: 450282
Abstract
Background: Bifenthrin is a synthetic pyrethroid insecticide derivativeof naturally occurring pyrethrins from chrysanthemum flowers. Bifenthrin is considered relatively safeand therefore incorporated as the active ingredient in preparations sold over the counter for householduse. Recent studies have raised concern that chronic exposure to pesticides in the home setting may increasethe risk for neurodegenerative diseases. To address this concer, in the present study, bifenthrin isadded to pre-differentiated PC12 and effect of bifenthrin on the retraction of existing neurites is observeda model for neurodegeneration. Material/Methods: PC12 cells were differentiated with nerve growth factorfor twenty-four hours and then treated with what was determined to be a sublethal dose of bifenthrinfor up to an additional 48 hours. The percent of cells with neurites was assessed at various times beforeand after nerve growth factor treatment. Bifenthrin toxicity was determined using trypan blue exclusion.Results: Bifenthrin was not toxic to PC12 cells at concentrations ranging from 1x10[sup]-10[/sup] M to 1x10[sup]-4[/sup]M. Twenty-four hours after nerve growth factor treatment, a maximum percent of cells had formed neuritesand with a treatment of 1x10[sup]-5[/sup] M bifenthrin, approximately 80% of these neurites retracted in within12 additional hours and almost all neurites had retracted within 48 hours. Trypan exclusion showed thatthese cells were viable. Conclusions: These data show that bifenthrin can stimulate the retraction ofneurites in the absence of frank toxicity.
Keywords: Cell Survival - drug effects, Insecticides - toxicity, Lindane - toxicity, Models, Neurological, Nerve Degeneration - pathology, Nerve Growth Factor - pharmacology, Neurites - pathology, Neurons - pathology, Pyrethrins - toxicity
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952